Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models

Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models

Intraperitoneal (IP) chemotherapy for ovarian cancer treatment prolongs overall survival by 16 months compared to intravenous chemotherapy but is not widely practiced due to catheter-related complications and complexity of administration. An implantable, nonresorbable IP microdevice was used to rele...

Full description

Bibliographic Details
Main Authors: Na, Young Jeong (Author), Fulci, Giulia (Author), del Carmen, Marcela G. (Author), Birrer, Michael J. (Author), Ye, Hongye (Contributor), Tanenbaum, Laura Melanie (Contributor), Mantzavinou, Aikaterini (Contributor), Cima, Michael J. (Author)
Other Authors: Harvard University- (Contributor), Massachusetts Institute of Technology. Department of Materials Science and Engineering (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor), Cima, Michael J (Contributor)
Format: Article
Language:English
Published: Elsevier, 2017-01-12T19:59:23Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items